Hepatitis B and hepatitis C virus and chronic kidney disease

Acta Gastro-Enterologica Belgica

Volumn 73, Issue 4, 2010, Pages 465-471

  Fabrizi, F ^a   Martin, P ^b   Messa, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Dialysis; Hepatitis b virus; Hepatitis c virus; Kidney transplantation

Indexed keywords

ADEFOVIR; AZATHIOPRINE; CALCINEURIN INHIBITOR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELBIVUDINE; TENOFOVIR;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DISEASE; CHRONIC GLOMERULONEPHRITIS; CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTORY OF MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER DISEASE; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; RISK; SEPSIS; SURVIVAL; VIRUS REPLICATION; VIRUS TRANSMISSION; DISEASE TRANSMISSION; KIDNEY DISEASE; RENAL REPLACEMENT THERAPY; REVIEW; VIROLOGY;

CHRONIC DISEASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVER DISEASES; RENAL DIALYSIS;

EID: 79952169700     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int., 2008, 73 (Suppl. 109): S1-S99.
2. FABRIZI F., MANGANO S., ALONGI G., BISEGNA S., FINAZZI S., LUNGHI G., PONTICELLI C. Influence of hepatitis B virus viremia upon serum aminotransferase activity in dialysis population. Int. J. Artif. Organs, 2003, 26: 1048-1055.
3. MARZANO A., ANGELUCCI E., ANDREONE P., BRUNETTO P., BRUNO R., BURRA P., CARACENI P., DANIELE B., DI MARCO V., FABRIZI F., FAGIUOLI S., GROSSI P., LAMPERTICO P., MELICONI R., MANGIA A., PUOTI M., RAIMONDO G., SMEDILE A.; ITALIAN ASSOCIATION FOR THE STUDY OF THE LIVER. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig. Liver Dis., 2007, 39: 397-408.
4. FINELLI L., MILLER J.T., TOKARS J.I., ALTER M.J., ARDUINO M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin. Dial., 2005, 18: 52-61.
5. BURDICK R.A., BRAGG-GRESHAM J.L., WOODS J.D., HEDDERWICK S.A., KUROKAWA K., COMBE C., SAITO A., LABRECQUE J., PORT F.K., YOUNG E.W. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int., 2003, 63: 2222-2229.
6. CHANDRA M., KHAJA M.N., HUSSAIN M.M., PODURI C.D., FAREES N., HABEEB M.A., KRISHNAN S., RAMAREDDY G.V., HABIBULLAH C.M. Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology, 2004, 47: 374-376.
7. YAKARYILMAZ F., GURBUZ OA., GULITER S., MERT A., SONGUR Y., KARAKAN T., KELES H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren. Fail., 2006, 28: 729-735.
8. JOHNSON D.W., DENT H., YAO Q., TRANAEUS A., HUANG C.C., HAN D.S., JHA V., WANG T., KAWAGUCHI Y., QIAN J. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol. Dial. Transplant., 2009, 24: 1598-1603.
9. FABRIZI F., LUNGHI G., ALONGI G., AUCELLA F., BARBISONI F., BISEGNA S., CORGHI E., FARANNA P., MANGANO S., ROMEI-LONGHENA G., MARTIN P. Kinetics of hepatitis B virus load and haemodialysis: a prospective study. J. Viral Hep., 2008, 15: 917-921.
10. JHA R. et al. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J. Nephrol., 1993, 6: 98-103.
11. JOSSELSON J., KYSER B., WEIR M., SADLER J. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am. J. Kidney Dis., 1987, 6: 456-461.
12. FABRIZI F., DE VECCHI A.F., QURESHI A.R., AUCELLA F., LUNGHI G., BRUHFELD A., BISEGNA S., MANGANO S., LIMIDO A., VIGILANTE D., FORCELLA M., DELLI CARRI P., MARTIN P. Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. Int. J. Artif. Organs, 2007, 30: 6-15.
13. FABRIZI F., MARTIN P., DIXIT V., KANWAL F., DULAI G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant., 2005, 5: 2913-2921.
14. YAÈ D., TANG C., YUNG S., CHOY B., YUEN M., CHAN T.M. Long-term outcome of renal transplant recipients with chronic hepatitis B infectionimpact of antiviral treatments. Transplantation, 2010, 90: 325-330.
15. FARZA H., SALMON A.M., HADCHOUEL M., MOREAU J.L., BABINET C., TIOLLAIS P., POURCEL C. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc. Natl. Acad. Sci., 1987, 84: 1187-1191.
16. MC MILLAN J., SHAW T., ANGUS P., LOCARNINI S. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology, 1995, 22: 36-43.
17. COTE P., TENNANT B., BALDWIN B., KORBA B., GERIN J.L. Modulation of WHV infection and disease with cyclosporine A and dexamethasone. International Symposium on Viral Hepatitis and Liver Disease (Houston, 1990).
18. GROTZ W., RASENACH J., BENZING T., BERTHOLD H., PETERS T., WALTER E., SCHOLLMEYER P., RUMP L. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin. Nephrol., 1998, 49: 385-388.
19. BOYACIOGLU S., GUR G., GURSOY M., OZDEMIR N. Lamivudine in renal transplant candidates with chronic hepatitis B virus infection. Transplant. Proc., 2002, 34: 2131-2132.
20. FONTAINE H., THIERS V., CHRETIEN Y., ZYLBERBERG H., POUPON R.E., BRECHOT L., LEGENDRE C., KREIS H., POL S. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation, 2000, 27: 2090-2094.
21. LAPINSKI TW., FLISIAK R., JAROSZEWICZ J., MICJALEWICZ M., KOWALCZUK O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J. Gastroenterol., 2005, 11: 400-402.
22. SCHMILOVITZ-WEISS H., MELZER E., TUR-KASPA R., BEN-ARI Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J. Clin. Gastroenterol., 2003, 37: 64-67.
23. FABRIZI F., DULAI G., DIXIT V., BUNNAPRADIST S., MARTIN P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation, 2004, 77: 859-864.
24. VIGANÒ M., COLOMBO M., AROLDI A., LUNGHI G., MANENTI E., PONTICELLI C., LAMPERTICO P. Long-term lamivudine monotherapy in renal transplant recipients with hepatitis B-related cirrhosis. Antivir. Ther., 2005, 10: 709-713.
25. AHN H.J., KIM M.S., KIM Y.S., KIM S.I., HUH KH., JU M.K., AHN S.H., HAN K.H. Clinical outcome of renal transplantation in patients with pretransplant hepatitis B surface antigen. J. Med. Virol., 2007, 79: 1655-1663.
26. FONTAINE H., VALLET-PICHARD A., CHAIX ML., CURRIE G., SERPAGGI J., VERKARRE V., VARAULT A., MORALES E., NALPAS B., BROSGART C., POL S. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation, 2005, 80: 1086-1092.
27. KAMAR N., MILIOTO O., ALRIC L., EL KAHWAJI L., VINTAULT O., LAVAYSSIERE L., SAUNE K., IZOPET J., ROSTAING L. Entecavir therapy for adefovir -resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation, 2008, 86: 611-614.
28. LEZAIC V., STOSOVIC M., MARINKOVIC J., RANGELOV V., DJUKANOVIC L. Hepatitis B and hepatitis C virus infection and outcome of hemodialysis and kidney transplant patients. Ren. Fail., 2008, 30: 81-87.
29. KALANTAR-ZADEH K., KILPATRICK R.D., MCALLISTER C., MILLER L.G., DAAR E., GJERTSON W., KOPPLE J.D., GREENLAND S. Hepatitis C virus and death risk in hemodialysis patients. J. Am. Soc. Nephrol., 2007, 18: 1584-1593.
30. FABRIZI F., TAKKOUCHE B., LUNGHI G., DIXIT V., MESSA P., MARTIN P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J. Viral Hepat., 2007, 14: 697-703.
31. AFSAR B., ELSURER R., SEZER S., OZDEMIR N. Quality of life in haemodialysis patients: hepatitis C virus makes sense. Int. J. Urol. Nephrol., 2009, 41: 1011-1019.
32. FABRIZI F., MARTIN P., DIXIT V., BUNNAPRADIST S., DULAI G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant., 2005, 5: 1452-1461.
33. WOLFFENBUTTEL L., POLI D., MANFRO R., GONCALVES L. Cyclosporine pharmacokinetics in anti-HCV positive patients. Clin. Transplant., 2004, 18: 654-680.
34. MANDAL A.K., KRAUS E.S., SAMANIEGO M., RAI R., HUMPHREYS S.L., RATNER L.E., MALEY W.R., BURDICK J.F. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin. Transplant., 2000, 14: 391-396.
35. WOODSIDE K.J., ISHIHARA K., THEISEN J.E., EARLY M.G., COVERT L.G., HUNTER G.C., GUGLIUZZA K.K., DALLER J.A. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-year outcome. Clin. Transplant., 2003, 17: 433-437.
36. BUCCI J.R., MATSUMOTO C., SWANSON S., AGODOA L., HOLTZMULLER K., PETERS T., ABBOTT K.C. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J. Am. Soc. Nephrol., 2002, 13: 2974-2982.
37. ABBOTT K.C., BUCCI J., MATSUMOTO C., SWANSON S.J., AGODOA L., HOLTZMULLER K., CRUESS D.F., PETERS T.G. Hepatitis C and renal transplantation in the era of modern immunosuppression. J. Am. Soc. Nephrol., 2003, 14: 2908-2918.
38. ABBOTT K.C., LENTINE K.L., BUCCI J.R., AGODOA L.Y., PETERS T.G., SCHNITZLER M.A. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in waitlisted longterm dialysis patients. Am. J. Transplant., 2004, 4: 2032-2037.
39. KUCIRKA L.M., SINGER A.L., ROS R., MONTGOMERY R., DAGHER N., SEGEV D. Underutilization of hepatitis C positive kidneys for hepatitis C positive recipients. Am. J. Transplant., 2010, 10: 1238-1246.
40. FABRIZI F., DIXIT V., MESSA P., MARTIN P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Viral Hepat., 2008, 15: 79-88.
41. SPOREA I., POPESCU A., SIRLI R., GOLEA O., TOTOLICI C., DANILA M., VERNIC C. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J. Gastroenterol., 2006, 12: 4191-4194.
42. DZEKOVA P., ASAN A., SELIM G., GELEV S., TRAJCESKA L., AMITOV V., SELJA N., ZABZUH M., MENA S., GASEVA M., SIKOLE A. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients. Int. J. Artif. Organs, 2009, 32: 180-184.
43. FABRIZI F., DIXIT V., MESSA P., MARTIN P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Med. Virol., 2010, 82: 768-775.
44. BRUCHFELD A., LINDAHL K., REICHARD O., CARLSSON T., SCHVARCZ R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J. Viral Hepat., 2006, 13: 316-321.
45. RENDINA M., SCHENA A., CASTELLANETA N., LOSITO F., AMORUSO A., STALLONE G., SCHENA F.P., DI LEO A., FRANCAVILLA A. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J. Hepatol., 2007, 46: 768-774.
46. HAKIM W., SHEIKH S., INAYAT I., CALDWELL C., SMITH D., LORBER M., FRIEDMAN A., HAIN D., BIA M., FORMICA R., MEHAL W. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J. Clin. Gastroenterol., 2009, 43: 477-481.
47. ROSTAING L., MODESTO A., BARON E., CISTERNE J., CHABANNIER M., DURAND D. Acute renal failure in kidney transplant patients treated with interferon alpha2b for chronic hepatitis C. Nephron, 1996, 74: 512-516.
48. BAID S., TOLKOFF-RUBIN S., SAIDMAN S., CHUNG R., WILLIAMS W., AUCHINLOSS H., COLVIN R., DEL MONICO F., COSIMI A., PASCUAL M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant., 2003, 3: 74-78.
49. SHARMA R., BANSAL S., GUPTA A., GULATI S., KUMAR A., PRASAD N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin. Transplant., 2006, 20: 677-683.
50. PAGEAUX G., HILLERET M., GARRIGUES V., BISMUTH M., AUDIN-MAMLOUK K., ZARSKI J.P., MOURAD G. Pegylated interferon alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transplant. Int., 2009, 22: 562-567.
51. CHAN T.M., HO S.K., TANG C.S., TSE K.C., LAM M.F., LAI K.N., YUNG S. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton), 2007, 12: 11-7.
52. AMARAPURKAR D.N., PATEL N.D., KIRPALANI A.L. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop. Gastroenterol., 2007, 28: 16-8.
53. AYAZ C., CELEN M.K., YUCE U.N., GEYIK M.F. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J. Gastroenterol., 2008, 14: 255-9.
54. UCMAK H., KOKOGLU O.F., HOSOGLU S., DOGAN E., SAYARLIOGLU H., KUZHAN N., ISIK I.O. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren. Fail., 2008, 30: 227-32. Erratum in: Ren. Fail., 2008, 30: 343. Ucmaky, Hasan (corrected to Ucmak, Hasan); Kokoglu, Omer Faruk (corrected to Kokoglu, Omer Faruk).
55. AKHAN S.C., KALENDER B., RUZGAR M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection, 2008, 36: 341-4.